HomePeptides › Argireline

Argireline

Acetyl hexapeptide-8, Acetyl hexapeptide-3

Tier 3 · Limited Human Data
Class
SNAP-25 mimetic hexapeptide
Molecular target
SNARE complex assembly
Sequence / structure
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
Evidence tier
Tier 3 — Limited Human Data
Category
Cosmetic & Topical
Emergency card
Signs something is wrong

Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.

What to do now

Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.

When it is an emergency

Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.

This is not permission or instruction to use this compound. It is harm-reduction information for someone who has already decided to, so that a bad reaction is recognised and treated. When in doubt, get help — embarrassment is survivable.

Biology & mechanism

Marketed as “topical Botox”, and the mechanism is a real one, borrowed honestly: the sequence mimics the N-terminal end of SNAP-25, a SNARE protein required for vesicle fusion at the neuromuscular junction. By competing for a position in the SNARE complex it is proposed to destabilise assembly and reduce acetylcholine release, softening muscle contraction. Botulinum toxin cleaves SNAP-25 outright; this competes with it — a far weaker intervention.

What the research actually shows

The honest limitation is delivery, not mechanism. It is a charged hydrophilic hexapeptide, and the stratum corneum is a formidable barrier to exactly that kind of molecule. Manufacturer-sponsored studies report modest wrinkle-depth reductions; independent evidence is thinner, and how much peptide reaches the neuromuscular junction of a facial muscle through intact skin is the question the marketing does not address.

Regulatory status

A cosmetic ingredient, requiring no FDA pre-approval. Cosmetic status permits appearance claims only. A product genuinely claiming to affect muscle function would be making a drug claim.

Safety signals

Topical use has a long commercial record and a benign safety profile. The realistic risk is disappointment rather than harm.

Clinical trial dosing — what the studies actually used

Topical cosmetic use, typically around 5–10% in a formulation. Appearance claims only; it is not injected.

Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.

We report study doses, not protocols

Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.

References & further reading

Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.

Important notice Forge Bioenergy publishes scientific reference information only. Nothing on this site is medical advice, a therapeutic claim, or a recommendation to use any substance in humans. Many peptides described here are not approved by the FDA for any use, and several are approved only for narrow indications under prescription. We do not publish dosing, administration, or usage protocols. Consult a licensed physician before making any medical decision.